Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 433,300 shares, anincreaseof878.1% from the July 15th total of 44,300 shares. Based on an average trading volume of 370,900 shares, the short-interest ratio is currently 1.2 days. Currently,1.8% of the shares of the company are short sold. Currently,1.8% of the shares of the company are short sold. Based on an average trading volume of 370,900 shares, the short-interest ratio is currently 1.2 days.

Institutional Trading of Anebulo Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new position in shares of Anebulo Pharmaceuticals in the 1st quarter valued at approximately $62,000. Nantahala Capital Management LLC raised its position in shares of Anebulo Pharmaceuticals by 494.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,036,325 shares of the company’s stock valued at $5,101,000 after buying an additional 2,525,252 shares in the last quarter. Finally, 22NW LP raised its position in shares of Anebulo Pharmaceuticals by 188.2% in the 4th quarter. 22NW LP now owns 15,467,300 shares of the company’s stock valued at $25,985,000 after buying an additional 10,101,010 shares in the last quarter. Institutional investors and hedge funds own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Stock Up 1.7%

Shares of Anebulo Pharmaceuticals stock opened at $2.44 on Friday. Anebulo Pharmaceuticals has a twelve month low of $0.80 and a twelve month high of $3.42. The company has a 50-day simple moving average of $1.95 and a two-hundred day simple moving average of $1.48. The stock has a market capitalization of $100.24 million, a price-to-earnings ratio of -9.38 and a beta of -0.88.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, sell-side analysts anticipate that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Maxim Group downgraded shares of Anebulo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 23rd.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.